Adverse events of neoadjuvant chemotherapy and immunotherapy for muscle-invasive bladder cancer in the real world and literature review
Objective:To investigate the adverse events(AEs)occurring after neoadjuvant chemotherapy and immunotherapy in patients with muscle-invasive bladder cancer(MIBC)in the real world and evaluate the safety of the treatment.Methods:A retrospective analysis was conducted on patients with MIBC who received 4 cycles of gemcitabine plus cisplatin(GC)chemotherapy and tislelizumab at PLA General Hospital from January 2021 to De-cember 2023.Various AEs and postoperative complications(Clavien-Dindo grading)were collected.Results:Among the 36 patients,32 patients(88.89％)experienced at least one drug-related adverse event,and nausea(n=19,52.78％),neutropenia(n=16,44.44％),anorexia(n=16,44.44％),fatigue(n=14,38.89％),vomiting(n=12,33.33％),and pruritus(n=10,27.78％)were common.Five patients(13.89％)experienced Grade 3 adverse events related to neoadjuvant therapy.Postoperative complications included inflammatory bowel obstruction(n=5,22.73％),pelvic effusion(n=1,4.55％),abdominal infection(n=1,4.55％),and recto-vaginal fistula(n=1,4.55％)in 22 patients who undergoing radical cystectomy.Conclusion:For MIBC patients,the incidence of AEs associated with neoadjuvant chemotherapy and immunotherapy is relatively high,but the rate of severe AEs is low,indicating an overall high level of safety.
NETL
NSTL
万方数据
